Nivolumab as maintenance therapy following platinum‐based chemotherapy in EGFR ‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial

BACKGROUND: As the outcome of immunotherapy can be improved when concurrently or sequentially combined with cytotoxic chemotherapy or radiotherapy, we investigated the efficacy of immunotherapy maintenance following platinum‐based chemotherapy in epidermal growth factor receptor (EGFR)‐mutant non‐sm...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jiwon, Choi, Chang‐Min, Ji, Wonjun, Lee, Jae Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626224/
https://www.ncbi.nlm.nih.gov/pubmed/37699785
http://dx.doi.org/10.1111/1759-7714.15083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626224/
https://www.ncbi.nlm.nih.gov/pubmed/37699785
http://dx.doi.org/10.1111/1759-7714.15083

Ejemplares similares